Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

Molecular biology of PCSK9: its role in LDL metabolism.

Horton JD, Cohen JC, Hobbs HH.

Trends Biochem Sci. 2007 Feb;32(2):71-7. Epub 2007 Jan 9. Review.

PMID:
17215125
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.

Lose JM, Dorsch MP, Bleske BE.

Pharmacotherapy. 2013 Apr;33(4):447-60. doi: 10.1002/phar.1222. Review.

PMID:
23553812
[PubMed - indexed for MEDLINE]
3.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

PMID:
23973703
[PubMed - indexed for MEDLINE]
Free Article
4.

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Poirier S, Mayer G.

Drug Des Devel Ther. 2013 Oct 4;7:1135-48. doi: 10.2147/DDDT.S36984. eCollection 2013. Review.

PMID:
24115837
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.

Shen L, Peng H, Xu D, Zhao S.

Pharmacol Res. 2013 Jul;73:27-34. doi: 10.1016/j.phrs.2013.04.001. Epub 2013 Apr 8. Review.

PMID:
23578522
[PubMed - indexed for MEDLINE]
6.

Recent patents on PCSK9: a new target for treating hypercholesterolemia.

Li H, Li H, Ziegler N, Cui R, Liu J.

Recent Pat DNA Gene Seq. 2009;3(3):201-12. Review.

PMID:
19601924
[PubMed - indexed for MEDLINE]
7.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.

Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.

Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Review.

PMID:
21943799
[PubMed - indexed for MEDLINE]
8.

PCSK9: an emerging target for treatment of hypercholesterolemia.

Duff CJ, Hooper NM.

Expert Opin Ther Targets. 2011 Feb;15(2):157-68. doi: 10.1517/14728222.2011.547480. Epub 2011 Jan 5. Review.

PMID:
21204732
[PubMed - indexed for MEDLINE]
9.

PCSK9: a key modulator of cardiovascular health.

Seidah NG, Awan Z, Chrétien M, Mbikay M.

Circ Res. 2014 Mar 14;114(6):1022-36. doi: 10.1161/CIRCRESAHA.114.301621. Review.

PMID:
24625727
[PubMed - indexed for MEDLINE]
10.

Unravelling the functional significance of PCSK9.

Lambert G.

Curr Opin Lipidol. 2007 Jun;18(3):304-9. Review.

PMID:
17495605
[PubMed - indexed for MEDLINE]
11.

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.

Maxwell KN, Breslow JL.

Curr Opin Lipidol. 2005 Apr;16(2):167-72. Review.

PMID:
15767856
[PubMed - indexed for MEDLINE]
12.

Anti-PCSK9 therapies for the treatment of hypercholesterolemia.

Hooper AJ, Burnett JR.

Expert Opin Biol Ther. 2013 Mar;13(3):429-35. doi: 10.1517/14712598.2012.748743. Epub 2012 Dec 17. Review.

PMID:
23240807
[PubMed - indexed for MEDLINE]
13.

Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.

Banaszewska A, Piechota M, Plewa R.

Cell Mol Biol Lett. 2012 Jun;17(2):228-39. doi: 10.2478/s11658-012-0006-7. Epub 2012 Feb 7. Review.

PMID:
22311433
[PubMed - indexed for MEDLINE]
14.

Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.

Cao G, Qian YW, Kowala MC, Konrad RJ.

Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):238-43. Review.

PMID:
19075777
[PubMed - indexed for MEDLINE]
15.

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C.

Hum Mutat. 2009 Apr;30(4):520-9. doi: 10.1002/humu.20882. Review.

PMID:
19191301
[PubMed - indexed for MEDLINE]
16.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
[PubMed - indexed for MEDLINE]
17.

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

Costet P, Krempf M, Cariou B.

Trends Biochem Sci. 2008 Sep;33(9):426-34. doi: 10.1016/j.tibs.2008.06.005. Epub 2008 Jul 30. Review.

PMID:
18672372
[PubMed - indexed for MEDLINE]
18.

Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.

Basak A, Palmer-Smith H, Mishra P.

Protein Pept Lett. 2012 Jun 1;19(6):575-85. Review.

PMID:
22519528
[PubMed - indexed for MEDLINE]
19.

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Stein EA, Swergold GD.

Curr Atheroscler Rep. 2013 Mar;15(3):310. doi: 10.1007/s11883-013-0310-3. Review.

PMID:
23371064
[PubMed - indexed for MEDLINE]
20.

New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.

Stefanutti C, Morozzi C, Di Giacomo S.

Curr Med Chem. 2012;19(28):4861-8. Review.

PMID:
22963620
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk